These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 2786520

  • 41. Activity of ciprofloxacin against resistant clinical isolates.
    Kelley SG, Bertram MA, Young LS.
    J Antimicrob Chemother; 1986 Mar; 17(3):281-6. PubMed ID: 2939048
    [Abstract] [Full Text] [Related]

  • 42. LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity.
    Trager GM, White GW, Zimelis VM, Panwalker AP.
    Antimicrob Agents Chemother; 1979 Sep; 16(3):297-300. PubMed ID: 315753
    [Abstract] [Full Text] [Related]

  • 43. In-vitro activity of meropenem imipenem, the penem HRE 664 and ceftazidine against clinical isolates from West Germany.
    Bauernfeind A, Jungwirth R, Schweighart S.
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():73-84. PubMed ID: 2509418
    [Abstract] [Full Text] [Related]

  • 44. The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin.
    Neu HC, Chin NX, Jules K, Labthavikul P.
    J Antimicrob Chemother; 1986 Apr; 17(4):441-52. PubMed ID: 3486862
    [Abstract] [Full Text] [Related]

  • 45. Bactericidal activity of Sch 34343 alone and in combination with gentamicin.
    Shah PM, Schneider K, Stille W.
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():165-71. PubMed ID: 3897171
    [Abstract] [Full Text] [Related]

  • 46. In vitro antibacterial activity of men 10700, a new penem antibiotic.
    Varotto F, Parravidini E, De Luca M, Casini A, Fraschini F.
    Chemotherapy; 1999 Jun; 45(6):405-10. PubMed ID: 10567770
    [Abstract] [Full Text] [Related]

  • 47. Evaluation of BRL 42715, a beta-lactamase-inhibiting penem.
    Qadri SM, Ueno Y, Burdette M, Kroschinsky R, Almodovar E.
    Chemotherapy; 1991 Jun; 37(6):398-404. PubMed ID: 1760938
    [Abstract] [Full Text] [Related]

  • 48. Comparative synergistic activity of netilmicin-piperacillin versus gentamicin-piperacillin.
    Machka K, Baierl W, Braveny I.
    Eur J Clin Microbiol; 1982 Aug; 1(4):238-42. PubMed ID: 6217066
    [Abstract] [Full Text] [Related]

  • 49. Synergism of PS-5 with penicillins and cephalosporins in antimicrobial activity against beta-lactam-resistant gram-negative microorganisms.
    Sakamoto M, Ishikura T, Fukagawa Y.
    J Antibiot (Tokyo); 1984 Nov; 37(11):1414-22. PubMed ID: 6334679
    [Abstract] [Full Text] [Related]

  • 50. MEN 10700, a new penem antibiotic: in vitro antibacterial activity on clinical isolates.
    Ferrari L, Altamura M, De Luca M, Ceruti T.
    Chemotherapy; 2002 Mar; 48(1):15-20. PubMed ID: 11901251
    [Abstract] [Full Text] [Related]

  • 51. Synergy of fluoroquinolones with other antimicrobial agents.
    Neu HC.
    Rev Infect Dis; 1989 Mar; 11 Suppl 5():S1025-35. PubMed ID: 2505355
    [Abstract] [Full Text] [Related]

  • 52. Characterization of FCE 22101-resistant Enterobacteriaceae and the effect of FCE 22101 upon the activity of anti-pseudomonal beta-lactams for Pseudomonas aeruginosa.
    Piddock LJ, Traynor EA.
    J Antimicrob Chemother; 1991 Sep; 28(3):369-75. PubMed ID: 1960118
    [Abstract] [Full Text] [Related]

  • 53. In-vitro activity of two new quinolone antimicrobial agents, S-25930 and S-25932 compared with that of other agents.
    Neu HC, Chin NX.
    J Antimicrob Chemother; 1987 Feb; 19(2):175-85. PubMed ID: 3571042
    [Abstract] [Full Text] [Related]

  • 54. In vitro activity of ciprofloxacin compared with other agents against recent hospital isolates.
    Rubinstein E, Mark Z, Samra Y, Alkan M, Berger S.
    Chemioterapia; 1986 Apr; 5(2):75-82. PubMed ID: 2939966
    [Abstract] [Full Text] [Related]

  • 55. Newer carbapenems for urinary tract infections.
    Matsumoto T, Muratani T.
    Int J Antimicrob Agents; 2004 Sep; 24 Suppl 1():S35-8. PubMed ID: 15364304
    [Abstract] [Full Text] [Related]

  • 56. [The in vitro antibacterial activity of cefozopran against clinically isolated bacteria].
    Higurashi Y, Okuzumi K, Yoneyama A, Nakahara K.
    Jpn J Antibiot; 1997 Dec; 50(12):907-16. PubMed ID: 9545668
    [Abstract] [Full Text] [Related]

  • 57. Beta-lactamase stability of faropenem.
    Dalhoff A, Nasu T, Okamoto K.
    Chemotherapy; 2003 Sep; 49(5):229-36. PubMed ID: 14504433
    [Abstract] [Full Text] [Related]

  • 58. In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.
    Wise R, Andrews JM, Danks G.
    J Antimicrob Chemother; 1984 Mar; 13(3):237-44. PubMed ID: 6586712
    [Abstract] [Full Text] [Related]

  • 59. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006].
    Yamaguchi K, Ishii Y, Iwata M, Watanabe N, Uehara N, Yasujima M, Kasai T, Suwabe A, Yamahata K, Kaku M, Kanemitsu K, Imafuku Y, Nishiyama K, Murakami M, Yomoda S, Taniguchi N, Yamada T, Nomura F, Watanabe M, Kanno H, Aihara M, Maesaki S, Hashikita G, Kondo S, Misawa S, Horiuchi H, Tazawa Y, Nakashima H, Takemura H, Okada M, Yamazaki F, Horii T, Maekawa M, Baba H, Ishigo S, Fujita N, Komori T, Ichiyama S, Iinuma Y, Maeda S, Yamanaka K, Murata Y, Matsuo S, Kohno H, Kinoshita S, Fujita J, Negayama K, Murase M, Miyamoto H, Kusano N, Mihara E, Itaha H, Ono J, Yoshimura H, Yanagihara K, Matsuda J, Saikawa T, Hiramatsu K.
    Jpn J Antibiot; 2007 Dec; 60(6):344-77. PubMed ID: 18447206
    [Abstract] [Full Text] [Related]

  • 60. Tobramycin, amikacin, sissomicin, and gentamicin resistant Gram-negative rods.
    Drasar FA, Farrell W, Maskell J, Williams JD.
    Br Med J; 1976 Nov 27; 2(6047):1284-7. PubMed ID: 1000196
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.